IndustryCompany release

IM Cannabis sells German arm to CEO-controlled Slil, refocusing on Israel

IM Cannabis Corp. (IMCC) · Fri 13 Nov 2026

The company's nine-month MD&A says IMC Holdings, including Adjupharm, went to an entity controlled by chief executive Oren Shuster on 29 September 2026.

IM Cannabis has sold IMC Holdings to Slil.com Holding, an entity controlled by its chief executive, Oren Shuster, according to the company's management discussion and analysis for the nine months ended 30 September 2026. The transaction closed on 29 September 2026.

The sale takes out the company's German operations, which were run through Adjupharm, as well as its stakes in Xinteza and Shiran. What remains is a business centred on importing and distributing medical cannabis in Israel under an IMCA licence.

The disposal is a related-party transaction, as the buyer is controlled by the company's CEO. The summary available does not give the price, the terms or details of any approval process, so those points cannot be assessed here.

Separately, the company completed a 30-for-1 share consolidation on 27 August 2026. It carried this out to regain compliance with Nasdaq listing requirements.

What it means for your team

  • Teams working with IM Cannabis as a supplier or partner in Germany should check who now owns and operates the former Adjupharm business, as the sale moved it out of the group.
  • The company's remaining activity is Israeli import and distribution under an IMCA licence, so Israeli licensing and supply-chain compliance becomes the central regulatory exposure.
  • Because the buyer is controlled by the CEO, counterparties may wish to read the full MD&A for the transaction terms and governance details, which are not covered in the summary.

Company's press release (SEC filing): IM Cannabis Corp. ↗

Article written by VigiEye from the official source (IM Cannabis Corp.). Claims are the company's own. AI-assisted; check the source before acting.

More Industry All →